This article reviews critical steps involved in total clinical research process flow and discusses the drug development process and criteria for clinical phase designs and how we follow the guidelines that have been proposed for creating CRF designs and clinical trials design of total I, II, III, IV. Phases, double data entry, data lock system, CDISC standardization, data analysis and CSR files submitted to Food and Drug Administration (FDA). Generally many circumstances have occurred in Pharmaceutical industries for FDA approval process. As the burden increases on sponsors to be more effective with restricted resources and time, integrated tools has been setup that enables cost-effective performance of these studies and as so large Pharmaceutical firms will look for established, robust organizations that can provide the assistance needed to bring the clinical data to regulatory agencies much faster and less expensively. So proper clinical phase trials were designed and are important. Also, our objective was to reduce the clinical trials time duration and cost. It can be achieved by following the guidelines and knowing completely research person?#8364;™s responsibilities and providing much more reliable coordination between them and applying the advance data entry and analysis software tools. Benefit-risk profile expands with further study, and use of pharmaceutical company may meet with regulatory agencies to discuss interpretation of data and estimate the side effect reports. Prior to this utilize the persons who have awareness of all the steps involved in total clinical trial process flow, hence by this they can reduce the burden of sponsor and increase the performance of organizations. Finally we can assume this is one of the best ways to complete FDA approval process easily for any new drug or generic drugs.